Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT00085345. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study of Melphalan, Arsenic Trioxide, and Ascorbic Acid in Patients With Relapsed or Refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy, such as melphalan, arsenic trioxide, and ascorbic acid, work in different ways to stop cancer cells from dividing so they stop growing or die. Arsenic trioxide and ascorbic acid may also help melphalan kill more cancer cells by making them more sensitive to the drugs. PURPOSE: This phase II trial is studying how well giving melphalan together with arsenic trioxide and ascorbic acid works in treating patients with relapsed or refractory multiple myeloma.
Study identification
- NCT ID
- NCT00085345
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Interventions
- arsenic trioxide Drug
- ascorbic acid Drug
- melphalan Drug
- chemosensitization/potentiation Procedure
- chemotherapy Procedure
Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Jul 10, 2013
United States locations
- U.S. sites
- 19
- U.S. states
- 10
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Palo Verde Hematology Oncology | Glendale | Arizona | 85304 | — |
| Comprehensive Blood and Cancer Center | Bakersfield | California | 93309-0633 | — |
| Southbay Oncology / Hematology Medical Group | Campbell | California | 95008 | — |
| Not listed | Fountain Valley | California | 92708 | — |
| Hematology-Oncology Medical Group of Fresno, Incorporated | Fresno | California | 93720 | — |
| Hematology Oncology Medical Group of Orange County, Incorporated | Orange | California | 92868 | — |
| Cancer Care Associates Medical Group - Redondo Beach | Redondo Beach | California | 90277 | — |
| Redwood Regional Oncology Center - Sotoyome | Santa Rosa | California | 95405 | — |
| Cancer Prevention and Treatment Center at Dominican and Watsonville Community Hospital | Soquel | California | 95073 | — |
| San Diego Cancer Center - Vista | Vista | California | 92083 | — |
| Oncotherapeutics | West Hollywood | California | 90069 | — |
| Mount Sinai Comprehensive Cancer Center at Mount Sinai Medical Center | Miami Beach | Florida | 33140 | — |
| Atlanta Cancer Care - Roswell | Roswell | Georgia | 30076 | — |
| Tulane Cancer Center at Tulane University Hospital and Clinic | New Orleans | Louisiana | 70112-2699 | — |
| Center for Cancer and Blood Disorders at Suburban Hospital | Bethesda | Maryland | 20817 | — |
| William Beaumont Hospital - Royal Oak Campus | Royal Oak | Michigan | 48073 | — |
| Hackensack University Medical Center Cancer Center | Hackensack | New Jersey | 07601 | — |
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104-4283 | — |
| Utah Cancer Specialists - Administrative Office | Salt Lake City | Utah | 84106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00085345, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 10, 2013 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00085345 live on ClinicalTrials.gov.